Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03496545 · ClinicalTrials.gov registry record · Phase 1
Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT03496545 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 47 participants.
The verdict
NCT03496545, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the antipyretic effect of bromocriptine in critically-ill patients with acute neurologic injury and fever from infectious and non-infectious etiologies.
Interventions
- DRUG Bromocriptine 5 MG
- DRUG Acetaminophen 650 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-11-30 |
| Est. Completion | 2019-11-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03496545
The ClinicalTrials.gov registry entry for NCT03496545 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bromocriptine 5 MG is the first listed.
NCT03496545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03496545 about?
NCT03496545 is a clinical study titled "Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury". The purpose of this study is to evaluate the antipyretic effect of bromocriptine in critically-ill patients with acute neurologic injury and fever from infectious and non-infectious etiologies.
What is the current status of trial NCT03496545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2018-11-30. Estimated completion is 2019-11-02.
What interventions are being tested in trial NCT03496545?
The interventions under investigation include: Bromocriptine 5 MG (DRUG), Acetaminophen 650 MG (DRUG).
Who is sponsoring clinical trial NCT03496545?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.